I challenge you to listen to the latest edition of OvaView with Victoria Haverbusch and not get excited about #OvaWatch.This one-of-a-kind proprietary blood test has demonstrated its accuracy in assessing the risk of malignancy in women with an adnexal mass, a breakthrough by any measure. For far too long, a lack of confidence in non-invasive methods of assessing ovarian cancer risk has led us to resort to surgical intervention even though the vast majority of the masses turn out to be benign. Aspira Women's Health is going to change that. The use of #OvaWatch initial clinical assessment and ongoing mass monitoring can reduce unnecessary surgery and surgical menopause while simultaneously improving a clinician's ability to identify those patients that require additional care and clinical intervention. #obgyn #innovation #dx #ovariancancer #gynecology #womenshealth #nursepractitioner
Introducing a new “OvaView” summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process. #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth
It's inspiring to see how Aspira Women's Health is pushing the boundaries with #OvaWatch. The potential to reduce unnecessary surgeries and improve patient care is truly transformative. What do you think could be the next steps in increasing awareness and adoption among clinicians?